Where Does Guardant Health Stock Rank Among Competitors?
With Guardant Health surging 28% in a Day, it makes sense to re-evaluate vs its peers. Consistently assessing alternatives is core to a sound investment approach. Here is how Guardant Health (GH) stock stacks up against its peers in size, valuation, growth and margin.
- GH’s operating margin of -49.0% is negative, lowest among peers; QGEN has 25.6%.
- GH’s revenue growth of 30.4% in the last 12 months is strong, outpacing TMO, ILMN, QGEN, CSTL but lagging NTRA.
- GH gained 300.6% in the past year and trades at a PE of -28.9, outperforming its peers.
As a quick background, Guardant Health provides liquid biopsy tests, data, and analytics for advanced and early-stage cancer detection, including precision oncology solutions for treatment selection and colorectal cancer screening.
A single stock can be risky, but there is a huge value to a broader, diversified approach we take with the Trefis High Quality Portfolio. We go beyond just equities. Is a portfolio of 10% commodities, 10% gold, and 2% crypto in addition to equities and bonds likely to return more during the next 1-3 years, and protect you better if markets crash 20%? We have crunched the numbers.
| GH | TMO | NTRA | ILMN | QGEN | CSTL | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 11.5 | 210.3 | 26.4 | 15.5 | 10.0 | 0.7 |
| Revenue ($ Bil) | 0.9 | 43.2 | 2.0 | 4.3 | 2.0 | 0.3 |
| PE Ratio | -28.9 | 31.9 | -104.1 | 12.4 | 26.9 | -73.9 |
| LTM Revenue Growth | 30.4% | 2.0% | 44.4% | -3.3% | 5.1% | 20.4% |
| LTM Operating Margin | -49.0% | 18.2% | -14.9% | 19.2% | 25.6% | -6.7% |
| LTM FCF Margin | -29.1% | 14.3% | 5.3% | 23.9% | 24.3% | 10.0% |
| 12M Market Return | 300.6% | 1.4% | 52.5% | -32.9% | 10.3% | -29.9% |
Why does this matter? GH just went up 47.5% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell GH Stock to see if Guardant Health holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through GH Dip Buyer Analysis lens.
- With Strong Cash Flow, Deckers Outdoor Stock Poised to Rise?
- TOST Tops ServiceNow Stock on Price & Potential
- Better Value & Growth: CMG, YUM Lead Starbucks Stock
- APP Looks Smarter Buy Than Synopsys Stock
- Better Value & Growth: TPR, RL Lead Nike Stock
- FIX Tops Quanta Services Stock on Price & Potential
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| GH | 30.4% | 31.0% | 25.5% | 20.3% |
| TMO | 2.0% | 0.1% | -4.6% | 14.5% |
| NTRA | 44.4% | 56.7% | 32.0% | 31.1% |
| ILMN | -3.3% | -2.9% | -1.7% | 1.3% |
| QGEN | 5.1% | 0.7% | -8.2% | -4.9% |
| CSTL | 20.4% | 51.1% | 60.4% | 45.7% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| GH | -49.0% | -60.0% | -100.1% | -121.1% |
| TMO | 18.2% | 18.0% | 17.1% | 18.9% |
| NTRA | -14.9% | -13.1% | -41.2% | -66.0% |
| ILMN | 19.2% | 13.7% | -4.9% | 7.7% |
| QGEN | 25.6% | 10.1% | 22.7% | 26.9% |
| CSTL | -6.7% | 2.6% | -30.9% | -66.5% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| GH | -28.9 | -8.6 | -6.3 | -4.2 |
| TMO | 31.9 | 31.4 | 34.2 | 31.1 |
| NTRA | -104.1 | -103.7 | -16.6 | -7.2 |
| ILMN | 12.4 | -17.4 | -18.4 | -7.0 |
| QGEN | 26.9 | 118.6 | 29.9 | 27.6 |
| CSTL | -73.9 | 40.6 | -10.1 | -9.1 |
While peer comparison is critical, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.